GeneDx Holdings (WGS) Says Sequencing Guided Care In More Than 60% Of Patients
GeneDx Holdings Corp. 2026 Q3 - Results - Earnings Call Presentation
GeneDx to Participate in Upcoming Investor Conferences
GeneDx (WGS) Stock Looks About Right After Fresh Sales Progress
Is GeneDx Holdings (WGS) Undervalued After Third Quarter 2026 Results?
Why GeneDx Holdings Stock Just Dropped 16.6%
GeneDx Holdings Corp. Q3 2026 Earnings Call Summary
GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients
GeneDx To Present New Research At The National Society Of Genetic Counselors Conference, November 11-14; Data Show 62% Of Patients With Pathogenic Or Likely Pathogenic Findings Had Results Associated With Opportunities To Inform Medical Management
GeneDx (WGS) Q3 2026 Earnings Call Transcript
GeneDx Holdings Corp (WGS) (Q3 2026) Earnings Call Highlights: Revenue Hits $123. ...
BTIG Maintains Buy on GeneDx Holdings, Lowers Price Target to $85
GeneDx Q3 Earnings Call Highlights
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript
GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability
GeneDx shares tumble on lowered growth targets
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx Reports Third Quarter 2026 Financial Results
GeneDx Holdings Q3 2026 Earnings Call Transcript
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $482.324M Est
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.